课题基金 / 基金详情

A STUDY OF TYPE II ALVEOLAR EPITHELIAL CELLS AS INFECTION SITE OF ACID-FAST BACILLI

A STUDY OF TYPE II ALVEOLAR EPITHELIAL CELLS AS INFECTION SITE OF ACID-FAST BACILLI
Ⅱ型肺泡上皮细胞作为抗酸杆菌感染部位的研究
批准号:
10670545
负责人:
SATO Katsumasa
金额:
$1.54万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 2000

项目摘要

项目成果

SATO Katsumasa的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Antimicrobial effects of clarithromycin (CAM), KRM-1648 (KRM) and levofloxacin (LVFX) against Mycobacterium tuberculosis (MTB) or M.avium complex (MAC) residing in the A-549 human type II alveolar epithelial cells (A-549 cells) were less than the effects of the same drugs against the same organisms residing in Mono Mac 6 human macrophage-like cells (MM6-MΦ).2. Antimicrobial activities of these drugs against MTB and MAC adapted to an intramacrophagic environment (intracellularly adapted : I-type) and those passaged in the 7H9 liquid medium (extracellularly adapted : E-type) were studied. The antibacterial effect of CAM or LVFX against E-type MTB or MAC residing in MM6-MΦs or A-549 cells was stronerg than a case against I-type MTB or MAC within the same cells. On the other hand, the antibacterial effect of KRM for E-type MTB or MAC residing in both cells was weaker than a case for I-type organisms within the same cells.3. Mice were infected intratracheally with MTB or MAC, and the lung sections of the infected mice were observed with transmission electron photomicrographs. The infected bacteria were recognized in type II alveolar epithelial cells in addition to mature granulocytes and macrophages.4. Using a dual chamber system, we examined whether the humoral factor of the A-549 cells infected with MTB or MAC which were released, influenced the anti-MTB or the anti-MAC antibacterial activity of MM6-MΦs. The number of the MTB or MAC organisms residing in MM6-MΦs of the top-chamber was decreased by the existence of A-549 cells infected with the MTB or MAC.5. It was found that the humoral factor (s) that decreased the number of these bacteria might be TNF-α and/or GM-CSF with RT-PCR examination.
期刊论文(31)
专著(0)
科研奖励(0)
会议论文
Katsumasa Sato: "Prospects for development of new anti-microbials for clinical control of tuberculosis. In vitro antimicrobial activities of quinolones, refamycins and macrolides against Mycobacterium tuberculosis and M.avium complex : Attempt to establis
Katsumasa Sato:“开发用于临床控制结核病的新型抗微生物药物的前景。喹诺酮类、利福霉素和大环内酯类药物对结核分枝杆菌和鸟分枝杆菌复合体的体外抗菌活性:尝试建立
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Katsumasa Sato: "Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macro-phage-like cells and human alveolar epithelial cells Chemo
Katsumasa Sato:“苯并嗪诺福霉素 (KRM-1648) 和克拉霉素对小鼠腹膜巨噬细胞、人巨噬细胞样细胞和人肺泡上皮细胞内鸟分枝杆菌细胞内复合物的抗菌活性
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
赤木竜也: "マウス腹腔マクロファージのin vitro培養に伴う抗結核菌活性の変化について"結核. 75. 477-482 (2000)
Tatsuya Akagi:“与小鼠腹膜巨噬细胞体外培养相关的抗结核活性的变化”结核病。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Katsumasa Sato: "Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells"Journa
Katsumasa Sato:“苯并恶嗪诺福霉素 (KRM-1648) 和克拉霉素对小鼠腹膜巨噬细胞、人巨噬细胞样细胞和人肺泡上皮细胞内鸟分枝杆菌细胞内复合物的抗菌活性”杂志
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
29
    Nutritional Evaluation of Meals Provided for Children with Food Allergies in Childcare Centers
    • 批准号:
      24501013
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.33万
    • 财政年份:
      2012
    • 负责人:
      SATO Katsumasa
    • 依托单位:
    Immunostimulating effects of health foods on murine macrophage cell line
    • 批准号:
      19500700
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2007
    • 负责人:
      SATO Katsumasa
    • 依托单位:
    Roles of type II alveolar epithelial cells in T cell-dependent immune response in Mycobacterium tuberculosis infection
    • 批准号:
      13670601
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2001
    • 负责人:
      SATO Katsumasa
    • 依托单位:
    国内基金
    海外基金
    鲜驴乳中游离脂肪酸对Mycobacterium tuberculosis H37Rv活性的影响及机制研究
    • 批准号:
      31760442
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      38.0万元
    • 批准年份:
      2017
    • 负责人:
      许倩
    • 依托单位: